Fluoxetine reduced apoptosis and catalepsy and improved movement by decreasing GRP78, XBP1, CHOP, and caspase-3 levels in ROT-treated rats (Peng et al., 2018), suggesting therapeutic potential for PD patients with depression. This evidence concerns the gene CASP3 and major depressive disorder.